Navigation Links
HemoNIR™

ProductsHemoNIR™
Company NIR Diagnostics Inc.
Item HemoNIR™
Features 
  • Convenient, small hand held portable device
  • Instant results
  • Low unit price, low sample unit price
  • Reduces biohazard waste
  • Measures a board range of analytes
  • Pre-determine blood oxygen levels using pulse-oximetry
Description HemoNIR™ is a portable device that measures the ability of apersons blood to carry oxygen by monitoring functional vs. non functional hemoglobin.
Info NIR Diagnostics Inc.
Customer Service: (905) 854-5727
Web site: http://www.goodmedia.com/equicom/nir/web/index.cfm

Related medicine products :

1. Barrier (Filter) Tips, 10 l size - Pipetman
2. Pipetman Ultra U1000
3. Pipetman P1000
4. Pipetman P200
5. Pipetman Ultra U200
6. Pipetman P20
7. Pipetman Ultra U20
8. Pipetman Ultra U10
9. Pipetman P10
10. Pipetman P100
11. Pipetman Ultra U100
TAG: HemoNIR
Breaking Medicine Technology:Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 2Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 3Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 4Medco, State of Illinois and Community Retail Pharmacies Launch 'Wired' Collaborative Solution to Close Critical Medication-Related Gaps in Healthcare, Improving Outcomes and Lowering Costs 5FDA Launches Orphan Drug Workshop at KGI 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 2Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 3Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 4Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 5Sangamo BioSciences Announces Presentation of Preliminary Data From Phase 2 Study of SB-509 at International ALS Symposium 6Companion Life Adds Dental Tourism Option to Help Policyholders Save 60761 1Companion Life Adds Dental Tourism Option to Help Policyholders Save 60761 2Companion Life Adds Dental Tourism Option to Help Policyholders Save 60761 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 1SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 2SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 3SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 4SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 5SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 6SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 7SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 8SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 9SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 10SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 11SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 12SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 13SENOMYX ANNOUNCES CORPORATE UPDATE AND THIRD QUARTER 2009 FINANCIAL RESULTS 14735 14SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 14733 1SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 14733 2